3 unchanged sentences
In 2023, The Cigna Group declared and paid quarterly cash dividends of $1.23 per share of The Cigna Group common stock.
+Added: The Cigna Group paid quarterly cash dividends of $1.12 per share in 2022 and $1.00 per share in 2021.
+Added: On February 2, 2024, the Board of Directors declared the first quarter cash dividend of $1.40 per share of The Cigna Group common stock to be paid on March 21, 2024 to shareholders of record on March 6, 2024.
The Cigna Group currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders.
The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant.
−Removed: In 2021, The Cigna Group paid quarterly cash dividends of $1.00 per share of The Cigna Group common stock.
−Removed: In 2020, The Cigna Group paid a yearly cash dividend of $0.04 per share.
See Note 9 to the Consolidated Financial Statements for further information on dividend payments.
−Removed: For information on securities authorized for issuance under our existing equity compensation plans, see Item 12 under the heading "Security Ownership of Certain Beneficial Owners and Management and Rebated Stockholder Matters."
+Added: For information on securities authorized for issuance under our existing equity compensation plans, see Item 12 under the heading "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters."
+Added: Stock Price Performance Graph
+Added: The graph below compares the cumulative total shareholder return on our common stock for the five years ended December 31, 2023 with the cumulative total return of the Standard & Poor's ("S&P") 500 Index and the S&P 500 Health Care Index.
+Added: The stock performance shown in the graph is not intended to forecast or be indicative of future performance.
Issuer Purchases of Equity Securities
6 unchanged sentences
that may yet be purchased as part
−Removed: of publicly announced program (3)
+Added: of publicly announced program (3) (in millions)
October 1-31, 2023 1,520,890 $ 300.75 1,520,691 $ 1,346
−Removed: November 1-30, 2022 5,499,088 see (1) below 5,497,926 $ 4,165,793,043
+Added: November 1-30, 2023 131,656 $ 313.82 128,550 $ 1,306
December 1-31, 2023 3,213 $ 287.87 — $ 11,306
−Removed: Total 7,303,300 see (1) below 7,300,344 N/A
+Added: Total 1,655,759 $ 301.76 1,649,241 N/A
(1) Includes shares tendered by employees under the Company's equity compensation plans as follows:
1 unchanged sentence
Employees tendered 199 shares in October, 3,106 shares in November and 3,213 shares in December 2023.
−Removed: Amount purchased in November 2022 also reflects the final settlement of 1.9 million shares pursuant to the Accelerated Share Repurchase ("ASR") agreements.
−Removed: See Note 8 to the Consolidated Financial Statements for further details on the average share price for total shares purchased under the ASR agreements.
−Removed: Such repurchase was made pursuant to the Company's share repurchase program described in note (2), below.
−Removed: Average price paid per share for the period November 1 to November 30, 2022 for shares not purchased pursuant to the ASR agreements was $315.56.
(2) Additionally, the Company maintains a share repurchase program authorized by the Board.
3 unchanged sentences
The program may be suspended or discontinued at any time and does not have an expiration date.
−Removed: From January 1, 2023 through February 22, 2023, the Company repurchased 2.1 million shares for approximately $646 million, leaving repurchase authority at $2.9 billion as of February 22, 2023.
−Removed: (3) Approximate dollar value of shares is as of the last date of the applicable month.
−Removed: Stock Price Performance Graph
−Removed: The graph below compares the cumulative total shareholder return on our common stock for the five years ended December 31, 2022 with the cumulative total return of the Standard & Poor's ("S&P") 500 Index and the S&P 500 Health Care Index.
−Removed: The stock performance shown in the graph is not intended to forecast or be indicative of future performance.
+Added: In December 2023, the Board increased repurchasing authority by an additional $10.0 billion.
+Added: In February 2024, as part of our existing share repurchase program, we entered into accelerated share repurchase agreements ("2024 ASR agreements") to repurchase $3.2 billion of common stock in aggregate.
+Added: We received an initial delivery of approximately 7.6 million shares of our common stock representing $2.6 billion of the total $3.2 billion remitted.
+Added: Including the impact of the 2024 ASR agreements, from January 1, 2024 through February 28, 2024, we repurchased 10.1 million shares for approximately $4.0 billion.
+Added: Share repurchase authority was $7.3 billion as of February 28, 2024.
+Added: See Note 9 to the Consolidated Financial Statements for further information on our ASR agreements.
+Added: (3) Approximate dollar value of shares is as of the last date of the applicable month and excludes the impact of excise tax.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.